Payment overview · 2025
General Payments
$41.35
2 reported records · 2 companies
Healthcare provider profile · identity verified
Soe P. Kyaw, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAUGERTIES, NY · NPI 1154588713
Verified facts
What the public records show
CMS Open Payments records show Soe P. Kyaw, MD received $41.35 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.76 | 55.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.59 | 45.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $41.35 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 469 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 97 |
| Lisinopril | Lisinopril | 334 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 64 |
| Omeprazole | Omeprazole | 246 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 59 |
| Gabapentin | Gabapentin | 216 | 57 |
| Simvastatin | Simvastatin | 191 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 44 |
| Candesartan Cilexetil | Candesartan Cilexetil | 161 | 38 |
| Montelukast Sodium | Montelukast Sodium | 158 | 42 |
| Buspirone Hcl | Buspirone Hcl | 146 | 39 |
| Metformin Hcl | Metformin Hcl | 131 | 40 |
| Losartan Potassium | Losartan Potassium | 128 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 35 |
| Ezetimibe | Ezetimibe | 105 | 26 |
| Ozempic | Semaglutide | 97 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 22 |
| Azelastine Hcl | Azelastine Hcl | 82 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 13 |
| Sertraline Hcl | Sertraline Hcl | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 21 |
| Prednisone | Prednisone | 75 | 34 |
| Glipizide | Glipizide | 71 | 18 |
| Furosemide | Furosemide | 69 | 22 |
| Spironolactone | Spironolactone | 68 | 20 |
| Carvedilol | Carvedilol | 67 | 20 |
| Trazodone Hcl | Trazodone Hcl | 66 | 21 |
| Allopurinol | Allopurinol | 65 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Meloxicam | Meloxicam | 57 | 15 |
| Finasteride | Finasteride | 55 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 14 |
| Niacin Er | Niacin | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Atenolol | Atenolol | 46 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 19 |
| Alprazolam | Alprazolam | 43 | 14 |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Eliquis | Apixaban | 41 | 12 |
| Glimepiride | Glimepiride | 41 | 11 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Naproxen | Naproxen | 33 | 12 |
| Famotidine | Famotidine | 31 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 27 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 15 |
| Valsartan | Valsartan | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 21 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clonazepam | Clonazepam | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41.35 · 2 records | Novo Nordisk Inc | NUCALA, Ozempic, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error